(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/061287 A1

(51) International Patent Classification:
*A61K 31/57* (2006.01) *A61P 21/00* (2006.01)
*A61K 31/573* (2006.01)

(21) International Application Number:
PCT/US2021/051274

(22) International Filing Date:
21 September 2021 (21.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 63/081,073 | 21 September 2020 (21.09.2020) | US |
| 63/195,473 | 01 June 2021 (01.06.2021) | US |
| 63/214,908 | 25 June 2021 (25.06.2021) | US |

(71) Applicant: **REVERAGEN BIOPHARMA, INC.** [US/US]; 155 Gibbs Street, Suite #433, Rockville, Maryland 20850 (US).

(72) Inventors: **DAMSKER, Jesse**; 155 Gibbs Street, Suite #433, Rockville, Maryland 20850 (US). **HOFFMAN, Eric**; 155 Gibbs Street, Suite #433, Rockville, Maryland 20850 (US).

(74) Agent: **STEVENS, Lauren**; Global Patent Group, LLC, P.O. Box 1636, Canóvanas, 00729 (PR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2022/061287 A1

(54) Title: TREATMENT OF NF-κB-MEDIATED DISEASE





FIG. 1

(57) Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.

*[Continued on next page]*

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*